Case control study of antibodies to ENA in progressive systemic sclerosis patients

J Rheumatol. 1984 Jun;11(3):298-305.

Abstract

Sixteen antibody to extractable nuclear antigen (anti-ENA) (+) and 16 anti-ENA(-) progressive systemic sclerosis (scleroderma, PS) patients were matched for disease duration, age, and sex in a case control study of antibody to ENA (anti-ENA) in scleroderma. Anti-ENA (+) PSS patients more frequently fulfill only minor criteria for PSS than anti-ENA (-) PSS controls (31% vs 0%). Anti-ENA(+) patients had less skin and muscle involvement (p less than 0.05) than their matched controls and tended to overlap more with other diseases (3 vs 0 patients). Besides antinuclear antibody and ENA, no significant serological differences were found between the 2 groups.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antibodies, Antinuclear / immunology*
  • Antigens, Nuclear
  • Arthritis / etiology
  • Dermatitis / etiology
  • Female
  • Humans
  • Lupus Erythematosus, Systemic / immunology
  • Middle Aged
  • Nucleoproteins / immunology*
  • Raynaud Disease / etiology
  • Scleroderma, Systemic / complications
  • Scleroderma, Systemic / immunology*

Substances

  • Antibodies, Antinuclear
  • Antigens, Nuclear
  • Nucleoproteins